Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

This study has been terminated.
(After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible.)
Sponsor:
Information provided by:
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT00105313
First received: March 11, 2005
Last updated: June 12, 2007
Last verified: June 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given